Michael Szarek
About
Michael Szarek is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Economics and Econometrics.
According to data from OpenAlex, Michael Szarek has authored 127 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Surgery, 41 papers in Cardiology and Cardiovascular Medicine and 30 papers in Economics and Econometrics. Recurrent topics in Michael Szarek's work include Lipoproteins and Cardiovascular Health (70 papers), Health Systems, Economic Evaluations, Quality of Life (25 papers) and Antiplatelet Therapy and Cardiovascular Diseases (25 papers). Michael Szarek is often cited by papers focused on Lipoproteins and Cardiovascular Health (70 papers), Health Systems, Economic Evaluations, Quality of Life (25 papers) and Antiplatelet Therapy and Cardiovascular Diseases (25 papers). Michael Szarek collaborates with scholars based in United States, Canada and France. Michael Szarek's co-authors include Gregory G. Schwartz, Vera Bittner, Anders Olsson, John J.P. Kastelein, Philip J. Barter, John C. LaRosa, Scott M. Grundy, Philippe Gabríel Steg, Deepak L. Bhatt and Jaman Maroni and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
Michael Szarek
117 papers receiving 7.2k citations
Hit Papers
Peers
Michael Szarek
Heinz Drexel Austria
Maurizio Averna Italy
Barbara A. Hutten Netherlands
Gérald Luc France
Tim Crowe United States
Alberto Lorenzatti Argentina
Sergio Fazio United States
Gregory G. Schwartz United States
Eleanor Danielson United States
David Preiss United Kingdom
Citations per year, relative to Michael Szarek Michael Szarek (= 1×)
peers
Heinz Drexel
Countries citing papers authored by Michael Szarek
Since
Specialization
Citations
This map shows the geographic impact of Michael Szarek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Szarek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Szarek more than expected).
Fields of papers citing papers by Michael Szarek
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael Szarek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Szarek. The network helps show where Michael Szarek may publish in the future.
Co-authorship network of co-authors of Michael Szarek
This figure shows the co-authorship network connecting the top 25 collaborators of Michael Szarek. A scholar is included among the top collaborators of Michael Szarek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Szarek. Michael Szarek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ray, Kausik K., Michael Szarek, Ann Marie Návar, et al.. (2025). Effect of Obicetrapib on New Onset Diabetes In Patients with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy: Pooled Analyses of the Broadway and Brooklyn Trials. Journal of clinical lipidology. 19(3). e116–e117.
2.
Szarek, Michael, E. Sebastian Debus, Mark R. Nehler, et al.. (2025). Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. Journal of the American Heart Association. 14(21). e039752–e039752.
3.
Bossuyt, Patrick M., J. Wouter Jukema, L. Renee Ruhaak, et al.. (2025). Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. Arteriosclerosis Thrombosis and Vascular Biology. 45(11). 2111–2123.
4.
Yuan, Žhong, Bennett Levitan, Hsiaowei Deng, et al.. (2024). Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association. 13(8). e032782–e032782.
5.
Szarek, Michael, Philippe Gabríel Steg, J. Wouter Jukema, et al.. (2024). Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES. European Journal of Preventive Cardiology. 31(10). e75–e78.
6.
Bittner, Vera, Gregory G. Schwartz, Deepak L. Bhatt, et al.. (2024). Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study. Journal of clinical lipidology. 18(4). e548–e561.
7.
Mohammadi, Kusha, Gregory G. Schwartz, Philippe Gabríel Steg, et al.. (2023). Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Medicine. 12(16). 16859–16868.
8.
Szarek, Michael, J. Wouter Jukema, Deepak L. Bhatt, et al.. (2023). Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. Circulation. 149(3). 192–203.
9.
Szarek, Michael, Marco Valgimigli, Md. Shahidul Islam, et al.. (2023). Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. Canadian Journal of Cardiology. 39(10). 1315–1324.
10.
Berkowitz, Scott D., Rupert Bauersachs, Michael Szarek, et al.. (2022). Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. Journal of Thrombosis and Haemostasis. 20(5). 1193–1205.
11.
Hess, Connie N., Iris Baumgärtner, Sonia S. Anand, et al.. (2022). Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American Heart Association. 11(12). e024655–e024655.
12.
White, Harvey D., Gregory G. Schwartz, Michael Szarek, et al.. (2021). Alirocumab after acute coronary syndrome in patients with a history of heart failure. European Heart Journal. 43(16). 1554–1565.
13.
Schwartz, Gregory G., Philippe Gabríel Steg, Deepak L. Bhatt, et al.. (2021). Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. Circulation. 143(11). 1109–1122.
14.
Szarek, Michael, Michael N. Needle, Brian I. Rini, et al.. (2021). Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Clinical Genitourinary Cancer. 19(5). 468.e1–468.e5.
15.
Bhatt, Deepak L., Michael Szarek, Bertram Pitt, et al.. (2020). Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine. 384(2). 129–139.
16.
Bhatt, Deepak L., Michael Szarek, Philippe Gabríel Steg, et al.. (2020). Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine. 384(2). 117–128.
17.
Steg, Philippe Gabríel, Deepak L. Bhatt, Vera Bittner, et al.. (2020). Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal. 41(42). 4114–4123.
18.
Sinnaeve, Peter, Gregory G. Schwartz, Daniel Wojdyla, et al.. (2019). Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal. 41(24). 2248–2258.
19.
Amarenco, Pierre, et al.. (2006). Abstract 2985: Lipoprotein, Blood Pressure and Stroke Risk: Findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Circulation. 114.
20.
Kastelein, John J.P., Ingar Holme, Philip J. Barter, et al.. (2006). Abstract 3357: Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials. Circulation. 114.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Heinz Drexel Breakdown of academic impact, for papers by Maurizio Averna Breakdown of academic impact, for papers by Barbara A. Hutten Breakdown of academic impact, for papers by Gérald Luc Breakdown of academic impact, for papers by Tim Crowe Breakdown of academic impact, for papers by Alberto Lorenzatti Breakdown of academic impact, for papers by Sergio Fazio Breakdown of academic impact, for papers by Gregory G. Schwartz Breakdown of academic impact, for papers by Eleanor Danielson Breakdown of academic impact, for papers by David Preiss